title: Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
authors.affiliation: Ia Division of Medical Oncology, National Tumor Institute, Naples, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Comella
authors.forename: G
authors.initials: G
authors.lastname: Abate
authors.forename: M
authors.initials: M
authors.lastname: Fiore
authors.forename: G
authors.initials: G
authors.lastname: Di Finizio
authors.forename: D
authors.initials: D
authors.lastname: Zarrilli
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D015251:Epirubicin; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone